))
Communicable E1 - Late-breaker clinical trial results from ESCMID Global 2024: Should they change your practice?
Manage episode 417839353 series 3573752
Content provided by CMI Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by CMI Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CMI Communications editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global (ECCMID) in Barcelona, providing insights into the trials’ designs, results, and implications. The DOTS trial compared two doses of long-acting dalbavancin to standard of care in patients with complicated S. aureus bacteremia. GAME-CHANGER compared cefiderocol to standard of care for gram-negative infections. PediCAP compared oral step-down therapy with amoxicillin with or without clavulanic acid at shorter durations to the current WHO-recommended standard of five days of intravenous antibiotic therapy in children with severe pneumonia. Additional results from the MULTICAP and CLEEN trials, the CAMERA-2 follow-on in vitro analysis, and the Burkina Faso Escherichia coli transmission study are also discussed. Episode peer-reviewed by Dr. Yousra Kherabi.
8 episodes
Share
